Product Description
Mechanisms of Action: Unknown
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: India
Approved Indications: None
Known Adverse Events: None
Company: Duke University
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Brain Stem Cancer|Glioblastoma
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT00814593 |
CDR0000630437 | P2 |
Withdrawn |
Brain Stem Cancer|Glioblastoma |
2011-04-01 |
2022-09-24 |
Primary Endpoints |
Recent News Events
Date |
Type |
Title |
|---|